Bladder

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
30004
Chemoresection with 4 weekly intravesical instillations of mitomycin C versus transurethral resection (TUR) followed by one single immediate instillation of mitomycin C in single, small, papillary stage Ta, T1 bladder tumors : A prospective randomized phase III trial
16996U
Open label phase II study on RFS 2000 (9 Nitro-camptothecin,9-NC) administered as a "5days on-2days off" oral treatment in advanced/metastatic urothelial tract tumors
22971
A phase II feasibility study of combined accelerated external radiation and chemotherapy with 5FU and CDDP following transurethral resection in patients with muscle invasive transitional carcinoma of the bladder
30971
A feasibility study of thorough transurethral resection (TURB) and escalated dose M-VAC Chemotherapy as primary treatment of T2-T3a, N0-Nx, M0, transitional cell carcinoma of the bladder, with the intention of bladder preservation.
30952
Quarter dose BCG on a papillary superficial bladder cancer. A phase II study on a marker lesion
30932
Phase II study of 5-fluorouracil, Cisplatin and Interferon alpha in second line in advanced transitional cell cancer of the urothelial tract
30931
Phase II study of loboplatin in advanced urothelial tract tumors
30924
Randomized phase II / III study of high dose intensity M-VAC chemotherapy + G-CSF versus classic M-VAC in advanced urothelial tract tumors
30906
Phase III study to compare the efficacy of intravesical instillations of BCG versus Epirubicin in carcinoma in situ of the bladder
22871
External irradiation with etanidazole radiosensitizer in advanced bladder cancer. A pilot study
30901
A RANDOMIZED PHASE III TO COMPARE TUR AND YAG-LASER FOLLOWED BY INTRAVESICAL CHEMOPROPHYLAXIS WITH Epirubicin in SINGLE RECURRENT, MULTIPLE PRIMARY OR RECURRENT Ta-T1 TCC OF THE BLADDER
30897
Phase II study of Mitomycin C and intravesical immunotherapy with BCG-RIVM in recurrent superficial transitional cell carninoma of the bladder
30886
Phase II protocol to study mitomycin C in patients with advanced transitional cell carcinoma of the urinary tract resistant to or ineligible for first line chemotherapy
30869
Phase II - III prospective randomized study to assess the effect of epirubicin in multiple bladder cancer
30868
Randomized phase II study with (A) methotrexate, cisplatin and (B) vinblastine, methotrexate and cisplatin in patients with advanced transitional cell carcinoma of the urinary tract
30861
Phase II trial of intravesical instillation of BCG in carcinoma in situ of the urinary bladder
30864
Phase II chemoresection study of mitomycin C with a marker lesion followed by a phase III study randomizing between maintenance and no maintenance in multiple TaT1 bladder cancer
30863
Phase III prospective randomized trial for the study of TUR + a single intravesical instillation of Epirubicin versus TUR alone in single, primary or recurrent, Ta/T1 papillary carcinoma of the bladder.
30867
PHASE II STUDY OF Epirubicin IN ADVANCED TCC OF THE URINARY TRACT FOR PATIENTS RESISTANT TO OR INELIGIBLE FOR FIRST LINE CHEMOTHERAPY
30851
Phase II trial of Cisplatin and methotrexate in T3-4 N0-X M0 transitional cell carcinoma of the bladder
30911
Phase III trial of intravesical instillation of Epirubicin, BCG or BCG + INH in intermediate and high risk pTa-pT1 papillary carcinoma of the urinary bladder
30894
Phase III study of primary chemotherapy (CMV) in T2G3, T3 and T4a, NO-X, M0 transitional cell carcinoma of the bladder (MRC/EORTC Collaborative Study)
30994
 Randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder
30993
A randomized phase II trial of sequential chemo-immunotherapy versus immunotherapy alone in carcinoma in situ of the urinary bladder.
30987
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and cisplatin/gemcitabine in patients with metastatic or locally advanced urothelial cancer without prior systemic therapy.
30986
Randomized phase II/III study assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in previously untreated patients with advanced urothelial cancer ineligible for Cisplatin based chemotherapy.
30962
Comparative study of intravesical BCG standard dose long-term maintenance versus BCG 1/3 dose long-term maintenance versus BCG standard dose short-term maintenance versus BCG 1/3 dose short-term maintenance in intermediate and high risk Ta- T1 Papillary Carcinoma of the Urinary Bladder.
30061
Phase I study of cisplatin, gemcitabine (+ paclitaxel) and lapatinib as first line treatment in advanced/metastatic urothelial cancer
16997
 EORTC 16997 : A phase II study of SCH66336 (Farnesyl Protein Transferase Inhibitor) in combination with Gemcitabine as second line treatment in patients with advanced / metastatic urothelial tract tumor.

Back to Site-list